xCELLigence Immunotherapy Research Grant for development of more effective therapy for patients with glioblastoma

With the goal of developing a novel immunotherapy for patients with glioblastoma, the research grant winner will employ xCELLigence Real Time Cell Analysis technology to develop armored CAR-T cells.

Dr. Bryan Choi, a postdoctoral fellow in the Dr. Marcela V. Maus lab at Massachusetts General Cancer Center and Harvard Medical School, has been awarded the 2018 xCELLigence Immunotherapy Research Grant by ACEA Biosciences.

CAR-T cells to eliminate glioblastoma

The chimeric antigen receptor (CAR) T cells developed by Dr. Choi’s group are specific to a tumor mutation of epidermal growth factor receptor (EGFRvIII). In previous clinical trials, the CART-EGFRvIII cells were efficiently localized to intracerebral sites beyond the blood-brain-barrier (BBB) to eliminate EGFRvIII glioma. Dr. Choi’s research proposal is to modify these chimeric antigen receptor (CAR) T cells to secrete bispecific T-Cell engagers (BiTEs), with a goal to develop a more effective immunotherapy for patients with glioblastoma (GBM). The proposal was selected by the ACEA Research Grant Committee for its experimental design quality, and the exciting potential to further advance treatment of this deadly disease.

Dr. Choi is provided access to xCELLigence Real Time Cell Analysis instrumentation, and will include consumables for 6 months. During this time, Dr. Choi’s team will be testing the hypothesis that EGFRvIII CAR-T cells designed to secrete BiTEs (CAR.BiTE) will “enhance CAR therapy by reversing regulatory T cell mediated immune suppression and lead to potent and durable antitumor responses against even heterogeneous tumor.”

Apply now for your cell analysis application

ACEA Biosciences is now accepting applications for the next xCELLigence Research Grant funding period, which is open to all cell analysis applications. For 6 months, the research grant winner will be provided access to the xCELLigence Real Time Cell Analysis DP instrument, consumables, and consultation.

Click here to apply.

 

 
 

Passende Artikel

xCELLigence SP

Platzsparendes Single-Plate System im 96-well Format xCelligence SP: Single Plate System; 96 well E-Plates im Standard-Format mit geringem Raumbedarf im Inkubator für die Echtzeit Zellanalytik. Dynamische, markerfreie Echtzeit Zell-Analytik mit hoher Datenqualität, weitem Anwendungsbereich, vollständig automatischer Daten-Aufzeichnung und vielseitiger intuitiver Analysesoftware. Die überlegene Technologie zur...

Preis auf Anfrage

2801000

 
 

Kommentar schreiben

 

Die mit einem * markierten Felder sind Pflichtfelder.